In Vitro Resistance Models for Oncology Discovery

Drug resistance remains a major challenge in modern drug development, limiting the durability of many targeted therapies and oncology treatments. Although advances in precision medicine have enabled more effective therapeutic strategies, cancer cells can develop adaptive mechanisms that reduce treatment sensitivity, including target alteration, pathway reactivation, drug efflux activation, metabolic rewiring, DNA damage response changes, and phenotypic plasticity.

As emerging modalities such as antibody-drug conjugates (ADCs), targeted inhibitors, and combination therapies continue to advance, understanding and overcoming resistance mechanisms has become increasingly important during preclinical development. However, conventional drug-sensitive cell models often fail to capture clinically relevant resistance phenotypes, making it difficult to evaluate therapeutic durability, identify resistance vulnerabilities, and develop effective combination strategies.

ICE Bioscience provides customized drug-resistant cell line development and screening services by generating resistant models through continuous or stepwise drug exposure and gene-editing-based approaches. These models enable mechanism-of-resistance studies, biomarker discovery, vulnerability screening, and evaluation of next-generation therapeutic strategies across diverse target and modality areas.